175 related articles for article (PubMed ID: 17550851)
1. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Lisa F; Fierro MT
Haematologica; 2007 Jun; 92(6):784-94. PubMed ID: 17550851
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.
Nosari A; Tedeschi A; Ricci F; Montillo M
Haematologica; 2008 Feb; 93(2):e30-1. PubMed ID: 18245646
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
Lundin J; Hagberg H; Repp R; Cavallin-Ståhl E; Fredén S; Juliusson G; Rosenblad E; Tjønnfjord G; Wiklund T; Osterborg A
Blood; 2003 Jun; 101(11):4267-72. PubMed ID: 12543862
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
Alinari L; Geskin L; Grady T; Baiocchi RA; Bechtel MA; Porcu P
Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
[TBL] [Abstract][Full Text] [Related]
10. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
Novelli S; García-Muret P; Sierra J; Briones J
J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
[TBL] [Abstract][Full Text] [Related]
14. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab in refractory Sézary syndrome.
Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
[TBL] [Abstract][Full Text] [Related]
16. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Verstovsek S; Tefferi A; Kantarjian H; Manshouri T; Luthra R; Pardanani A; Quintás-Cardama A; Ravandi F; Ault P; Bueso-Ramos C; Cortes JE
Clin Cancer Res; 2009 Jan; 15(1):368-73. PubMed ID: 19118067
[TBL] [Abstract][Full Text] [Related]
19. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
